Founded in 2013 by a group of researchers, Oncostellae focuses on discovering and developing small molecule drugs for cancer treatment by generating pharmaceutical research programs around novel modulators of validated cancer targets. The company's strategy includes limited headcounts and subcontracting in vivo pharmacology, toxicology, and clinical trials to qualified providers. Oncostellae aims to license a clinical drug candidate, including intellectual property and preclinical/clinical data package, to a consolidated pharmaceutical or biotechnological company. The company has developed drug candidates for the treatment of Ulcerative Colitis and colon cancer, which are currently being evaluated in clinical studies in patients, with positive data expected by the end of 2023.